Back to top
more

Kamada (KMDA)

(Delayed Data from NSDQ)

$5.78 USD

5.78
34,571

-0.05 (-0.86%)

Updated Jul 19, 2024 04:00 PM ET

After-Market: $5.88 +0.10 (1.73%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (71 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Grab These 6 Stocks That Boast Substantial Net Profit Margin

by Zacks Equity Research

Here are six stocks with spectacular net profit margin that can contribute to making a winning portfolio.

Merrimack (MACK) Incurs Narrower-Than-Expected Loss in Q4

by Zacks Equity Research

Merrimack's (MACK) loss betters estimates in Q4. However, the company fails to earn any revenues in the period.

Focus on 6 Top-Ranked Stocks With Solid Net Profit Margin

by Zacks Equity Research

Here are six marvelous stocks with significant net profit margin that investors can bank on for remarkable returns.

Is Kamada (KMDA) a Great Value Stock Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Kamada (KMDA) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Kamada (KMDA) delivered earnings and revenue surprises of -350.00% and -42.37%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

The Zacks Analyst Blog Highlights: American River, BG Staffing, Evolution Petroleum, Kamada and Farmers & Merchants

by Zacks Equity Research

The Zacks Analyst Blog Highlights: American River, BG Staffing, Evolution Petroleum, Kamada and Farmers & Merchants

    Tirthankar Chakraborty headshot

    Dollar Strengthens on Turkey's Trouble: Top 5 Gainers

    by Tirthankar Chakraborty

    Lira loses more than 20% over the week as international markets react to the uncertainty over Turkey's capability to repay foreign-currency debts. Dollar hits a one-year high.

      Kamada (KMDA) Surpasses Q2 Earnings and Revenue Estimates

      by Zacks Equity Research

      Kamada (KMDA) delivered earnings and revenue surprises of 55.56% and 14.20%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

        Is Kamada (KMDA) Outperforming Other Medical Stocks This Year?

        by Zacks Equity Research

        Is (KMDA) Outperforming Other Medical Stocks This Year?

          4 Undervalued MedTech Stocks to Consider Amid Volatility

          by Zacks Equity Research

          Amid turbulences of the U.S. market, some value stocks of MedTech industry appear to be lucrative investment options.

            Kamada (KMDA) Gets FDA Approval for Rabies Vaccine

            by Zacks Equity Research

            Kamada Ltd. (KMDA) and partner Kedrion Biopharma and announced that FDA has approved Kedrab [rabies immune globulin (Human)] for post-exposure prophylaxis against rabies infection.

              Kamada Withdraws Inhaled AAT Marketing Application in EU

              by Zacks Equity Research

              Kamada Ltd.'s (KMDA) decided to withdraw the marketing authorization application (MAA) for its inhaled formulation of Alpha-1 Antitrypsin (AAT) in the EU.

                Kamada (KMDA) Posts Q1 Loss Wider than Expected, Sales Miss

                by Zacks Equity Research

                Kamada Ltd. (KMDA) reported adjusted loss of 11 cents in the first quarter of 2017, wider than the Zacks Consensus Estimate of a loss of 3 cents.

                  Puma (PBYI) Expands Study Cohort for Lead Candidate PB272

                  by Zacks Equity Research

                  Puma Biotechnology, Inc. (PBYI) has expanded the fourth cohort of the phase II SUMMIT study evaluating its lead candidate PB272 (neratinib) as a single agent in patients with solid tumors who have an activating HER2 mutation (basket study).

                    Evoke Diabetic Gastroparesis Drug Gimoti Positive in Phase III

                    by Zacks Equity Research

                    Pharma, Inc. (EVOK) announced additional data from a phase III trial on Gimoti (nasal delivery), a novel formulation of its marketed drug, metoclopramide, for diabetic gastroparesis in adult women.

                      Allergan (AGN) Liletta sNDA Accepted for Review in the U.S.

                      by Zacks Equity Research

                      Allergan plc (AGN) and partner Medicines360, a nonprofit global women's health pharmaceutical company, announced that the FDA has accepted a supplemental New Drug Application (sNDA) for its marketed intrauterine system (IUS), Liletta.

                        Allergan Natrelle Inspira Breast Implants Approved in the U.S.

                        by Zacks Equity Research

                        Allergan plc (AGN) announced that the FDA has approved Natrelle Inspira SoftTouch, a new medium firmness gel, or cohesive, implant option for breast reconstruction, augmentation or revision surgery.

                          Sanofi (SNY) Closes Business Exchange Deal with Boehringer

                          by Zacks Equity Research

                          Sanofi (SNY) announced the closing of a previously announced deal to exchange its Merial animal health business with Boehringer Ingelheim's consumer healthcare (CHC) segment. The transaction was signed in Jun 2016.